Qiagen N.V. (NYSE:QGEN) Morgan Stanley twenty third Annual International Healthcare Convention September 9, 2025 1:05 PM EDT
Firm Contributors
Roland Sackers – CFO, MD & Member of Administration Board
John Gilardi – VP & Head of Company Communications
Convention Name Contributors
Aisyah Noor – Morgan Stanley, Analysis Division
Presentation
Aisyah Noor
Fairness Analyst
So thanks for becoming a member of us right this moment. My title is Aisyah Noor, European Medtech analyst with Morgan Stanley. I’ve with me on the stage, Mr. Roland Sackers, CFO of QIAGEN. And for the primary time in my profession with Morgan Stanley, Mr. John Gilardi, IR of QIAGEN. For analysis disclosures, please examine morganstanley.com/researchdisclosures. However, sure, let’s begin.
Query-and-Reply Session
Aisyah Noor
Morgan Stanley, Analysis Division
Thanks, everybody, for being right here right this moment. Roland, for the good thing about traders, might you type of present a recap of your current second quarter earnings?
Roland Sackers
CFO, MD & Member of Administration Board
Pleased to take action, and thanks for having us. I’d clearly state that QIAGEN general had an excellent begin into the yr. We had an excellent progress fee, not solely within the first quarter, but in addition the second quarter got here in with a 6% general progress fee, which I do suppose, notably given the times, that are a bit extra risky, if you happen to suppose on the tutorial franchise right here in U.S. and even on China, exhibits the power of our general enterprise.
I do suppose it’s totally clearly additionally attributed to the truth that 85%/90% of our general enterprise is a consumer-related enterprise. So we’re clearly a part of each day operations in all completely different buyer teams. Simply as a recap, 50% of our revenues go to the medical settings, lab organizations; 50% go in what we name life science, together with pharma and utilized testing prospects.
The realm
